SNORA59A

Across TCGA pan-cancer cohorts, SNORA59A RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SNORA59A’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SNORA59A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNORA59A is over-expressed in tumor.

LIHC, KICH, and THCA are the cancer types where SNORA59A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNORA59A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.885	<.001	6	view →
KICH	All	II,III,IV	+0.475	.001	6	view →
THCA	Male	All	+0.948	.001	5	view →
UCEC	All	II,III,IV	+0.767	.032	4	view →
BLCA	All	All	+0.676	.007	4	view →
CHOL	All	All	+1.134	<.001	2	view →
READ	All	All	+0.891	.015	2	view →
KIRP	All	II,III,IV	+0.405	.049	1	view →
LUSC	All	All	+0.287	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SNORA59A–LIHC

Open the LIHC breakdown →